Literature DB >> 35387856

Multimodal Quality of Life Assessment in Post-9/11 Veterans With Epilepsy: Impact of Drug Resistance, Traumatic Brain Injury, and Comorbidity.

James J Gugger1, Eamonn Kennedy1, Samin Panahi1, David F Tate1, Ali Roghani1, Anne C Van Cott1, M Raquel Lopez1, Hamada Altalib1, Ramon Diaz-Arrastia1, Mary Jo Pugh1.   

Abstract

BACKGROUND AND OBJECTIVES: Epilepsy is defined by the occurrence of multiple unprovoked seizures, but quality of life (QOL) in people with epilepsy is determined by multiple factors, in which psychiatric comorbid conditions play a pivotal role. Therefore, understanding the interplay between comorbid conditions and QOL across epilepsy phenotypes is an important step toward improved outcomes. Here, we report the impact of QOL across distinct epilepsy phenotypes in a cohort of post-9/11 veterans with high rates of traumatic brain injury (TBI).
METHODS: This observational cohort study from the Veterans Health Administration included post-9/11 veterans with epilepsy. A process integrating an epilepsy identification algorithm, chart abstraction, and self-reported measures was used to classify patients into 1 of 4 groups: (1) epilepsy controlled with medications, (2) drug-resistant epilepsy (DRE), (3) posttraumatic epilepsy (PTE), or (4) drug-resistant PTE (PT-DRE). Summary scores for 6 QOL measures were compared across the groups after adjustment for age, sex, and number of comorbid conditions.
RESULTS: A total of 529 survey respondents with epilepsy were included in the analysis: 249 controls (i.e., epilepsy without DRE or PTE), 124 with DRE, 86 with PTE, and 70 with PT-DRE. DRE was more common in those with PTE compared with those with nontraumatic epilepsy (45% vs 33%, odds ratio 1.6 [95% CI 1.1-2.4], p = 0.01). Patients with PTE and PT-DRE had significantly more comorbid conditions in health records than those with nontraumatic epilepsy. Those with both PTE and DRE reported the lowest QOL across all 6 measures, and this persisted after adjustment for comorbid conditions and in further linear analyses. DISCUSSION: Among those with PTE, DRE prevalence was significantly higher than prevalence of nontraumatic epilepsies. PTE was also associated with higher burden of comorbidity and worse overall QOL compared to nontraumatic epilepsies. People with PTE are distinctly vulnerable to the comorbid conditions associated with TBI and epilepsy. This at-risk group should be the focus of future studies aimed at elucidating the factors associated with adverse health outcomes and developing antiepileptogenic therapies.
© 2022 American Academy of Neurology.

Entities:  

Mesh:

Year:  2022        PMID: 35387856      PMCID: PMC9071370          DOI: 10.1212/WNL.0000000000200146

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


  42 in total

Review 1.  Comorbidities of epilepsy: current concepts and future perspectives.

Authors:  Mark R Keezer; Sanjay M Sisodiya; Josemir W Sander
Journal:  Lancet Neurol       Date:  2015-11-06       Impact factor: 44.182

2.  QOLIBRI overall scale: a brief index of health-related quality of life after traumatic brain injury.

Authors:  Nicole von Steinbuechel; Lindsay Wilson; Henning Gibbons; Holger Muehlan; Holger Schmidt; Silke Schmidt; Nadine Sasse; Sanna Koskinen; Jaana Sarajuuri; Stefan Höfer; Monika Bullinger; Andrew Maas; Edmund Neugebauer; Jane Powell; Klaus von Wild; George Zitnay; Wilbert Bakx; Anne-Lise Christensen; Rita Formisano; Graeme Hawthorne; Jean-Luc Truelle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-31       Impact factor: 10.154

3.  Sensory dysfunction and traumatic brain injury severity among deployed post-9/11 veterans: a chronic effects of neurotrauma consortium study.

Authors:  Alicia A Swan; Jeremy T Nelson; Terri K Pogoda; Megan E Amuan; Faith W Akin; Mary Jo Pugh
Journal:  Brain Inj       Date:  2018-07-19       Impact factor: 2.311

4.  Post-traumatic epilepsy associations with mental health outcomes in the first two years after moderate to severe TBI: A TBI Model Systems analysis.

Authors:  Shannon B Juengst; Amy K Wagner; Anne C Ritter; Jerzy P Szaflarski; William C Walker; Ross D Zafonte; Allen W Brown; Flora M Hammond; Mary Jo Pugh; Timothy Shea; Jason W Krellman; Tamara Bushnik; Patricia M Arenth
Journal:  Epilepsy Behav       Date:  2017-06-26       Impact factor: 2.937

5.  An electric-field-responsive paramagnetic contrast agent enhances the visualization of epileptic foci in mouse models of drug-resistant epilepsy.

Authors:  Cong Wang; Wanbing Sun; Jun Zhang; Jianping Zhang; Qinghua Guo; Xingyu Zhou; Dandan Fan; Haoran Liu; Ming Qi; Xihui Gao; Haiyan Xu; Zhaobing Gao; Mei Tian; Hong Zhang; Jianhong Wang; Zixuan Wei; Nicholas J Long; Ying Mao; Cong Li
Journal:  Nat Biomed Eng       Date:  2020-09-28       Impact factor: 25.671

6.  Initial reliability and validity of the Ohio State University TBI Identification Method.

Authors:  John D Corrigan; Jennifer Bogner
Journal:  J Head Trauma Rehabil       Date:  2007 Nov-Dec       Impact factor: 2.710

7.  Is the underlying cause of epilepsy a major prognostic factor for recurrence?

Authors:  F Semah; M C Picot; C Adam; D Broglin; A Arzimanoglou; B Bazin; D Cavalcanti; M Baulac
Journal:  Neurology       Date:  1998-11       Impact factor: 9.910

8.  The role of comorbid psychiatric conditions in health status in epilepsy.

Authors:  John E Zeber; Laurel A Copeland; Megan Amuan; Joyce A Cramer; Mary Jo V Pugh
Journal:  Epilepsy Behav       Date:  2007-04-06       Impact factor: 2.937

9.  The Military Injuries: Understanding Post-Traumatic Epilepsy Study: Understanding Relationships among Lifetime Traumatic Brain Injury History, Epilepsy, and Quality of Life.

Authors:  Mary Jo Pugh; Eamonn Kennedy; James J Gugger; Jamie Mayo; David Tate; Alicia Swan; Jacob Kean; Hamada Altalib; Shaila Gowda; Alan Towne; Sidney Hinds; Anne Van Cott; Maria R Lopez; Carlos A Jaramillo; Blessen C Eapen; Randall R McCafferty; Martin Salinsky; Joyce Cramer; Katherine K McMillan; Andrea Kalvesmaki; Ramon Diaz-Arrastia
Journal:  J Neurotrauma       Date:  2021-10-15       Impact factor: 4.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.